Product News

Share this article:
GlaxoSmithKline says the US launch of HPV vaccine Cervarix will feature a slightly lower price than that of Merck's vaccine Gardasil, the Financial Times reports. GSK's new entrant will carry a wholesale cost of $386 for a three-course dose, compared with $399 for rival Gardasil, making the GSK vaccine more attractive for payers. The price strategy already has helped GSK win a vaccine contract in the UK.
Share this article:
You must be a registered member of MMM to post a comment.

This compelling e-book shares a wealth of insights designed to help members of sales forces connect with elusive HCPs. An expanded version has also been created that includes video interviews and other multimedia content. Click here for access.